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Abstract: 
5% of urothelial carcinoma occurs in the upper urinary tract (UUT), a challenging location to biopsy. We 
aim to evaluate concordance between biopsy, cytology, and resection specimens in a large upper tract 
urothelial carcinoma (UTUC) cohort.117 UTUC resections with UUT biopsy and/or cytology specimens 
from 2000-2016 were retrieved; pathologic material was re-reviewed, evaluated for concordance, and 
correlated with clinical information. 14% pre-operative biopsies, including 8 from renal pelvis and 6 from 
ureter, lacked neoplastic diagnoses. 77% diagnostic biopsies included subepithelial tissue; 11% 
demonstrated reclassification of grade and 30% demonstrated reclassification of invasion status. 26% of 
renal pelvis UTUC and 36% ureter UTUC were invasive only on resection. Of 18 UTUC reclassified from 
noninvasive high-grade papillary urothelial carcinoma (HGPUC) to invasive HGPUC, 39% had prior radical 
cystectomy (versus 8% invasive UTUC and 11% noninvasive UTUC with concordant biopsies). Most high-
grade UTUC (88%) and some low-grade UTUC (58%) resections had abnormal cytology results. Biopsy-
resection pairs with concordant invasion status and pairs with discordant invasion status showed similar 
rates of recurrence (38% versus 38%) and metastasis (25% versus 27%). 14% of UUT biopsies lacked 
diagnostic neoplastic material. Grade concordance between biopsy and resection was high (89%), but 
30% of cases showed invasion only on resection. Subepithelial tissue was less commonly present in 
ureter biopsies, particularly from mid or proximal ureter. UTUC in patients with prior cystectomy were 
more likely to show invasion on resection but not biopsy. 
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1. Introduction 
Upper tract (renal pelvis, ureter) urothelial carcinoma (UTUC) accounts for approximately 5% of 
urothelial carcinomas. [1,2] Diagnosis of urothelial carcinoma (UCa) often requires biopsy and/or 
cytology confirmation with demonstration of malignant cells. Urinary bladder lesions can be relatively 
easily accessed for biopsy during cystoscopy and bladder washing and voided urine cytology specimens 
most directly reflect the status of urothelium in the bladder on cytology specimens. Voided urine 
cytology has been demonstrated to be positive in approximately 25-72% of bladder UCa cases [3,4]; 
inclusion of suspicious diagnoses increases sensitivity to 89%. [5] In contrast, visualization of and access 
to the upper urinary tract is more technically challenging. [6] Given the greater level of difficulty 
involved in the detection and sampling of UTUC, it is not surprising that a significant subset of UTUC 
biopsies may demonstrate inadequate tissue for a pathologic diagnosis. [7, 8] Similarly, the sensitivity of 
selective upper urinary tract cytology has been estimated at 55-81%. [9, 10] 
In patients with high-risk UTUC, regardless of location, the first line treatment option in the majority of 
cases is a radical nephroureterectomy (RNU). [2] Classification of UTUC as high-risk is based on the 
presence of any concerning clinical/radiologic factors including the presence of hydronephrosis, tumor 
size >2 cm, multifocal disease, previous radical cystectomy for bladder cancer, or pathologic factors 
including high-grade cytology or upper tract biopsy with diagnosis of high-grade carcinoma  and 
presence of variant histology. [2] Detection of hydronephrosis/hydroureter on imaging is also thought to 
correlate with muscular invasion. 
There are few studies which have assessed the clinical accuracy of upper urinary tract biopsy and 
cytology in aiding clinical decision-making for UTUC patients. A large number of UTUC have been 
resected at Michigan Medicine, and in-house pre-operative upper urinary tract biopsy and cytology 
specimens are often obtained prior to surgery. Here, we aimed to evaluate the clinicopathologic 
features of a cohort with biopsy, cytology, and resection material in a large cohort of UTUC in order to 
assess concordance between different diagnostic modalities, as well as the effect of such concordance 
on clinical outcomes.  
 
2. Materials and Methods 
2.1 Cohort Selection 
With Institutional Review Board approval, cases of upper urinary tract urothelial carcinoma with radical 
nephroureterectomy (RNU) or ureterectomy (UT) performed between 2000 and 2016 were 
retrospectively identified from the surgical pathology archive at Michigan Medicine. Only cases with 
ipsilateral pre-operative upper urinary tract biopsy and/or selective cytology available for review were 
included, resulting in a final cohort of 117 surgical resections (RNU or UT) from 114 patients. 
2.2 Review of Patient Material  
 The biopsy, cytology, and surgical resection materials were re-reviewed by a genitourinary pathologist 
(RM), a cytopathologist (ML), and two pathology residents (CTS and SLS).  Pathologic features assessed 
in biopises included tumor type, grade, and presence of invasion into subepithelial connective tissue or 
deeper. Biopsies designated as non-neoplastic include both negative and non-diagnostic biopsies. The 
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pathologic features assessed in resections (RNU and UT) included tumor type, grade, stage, presence of 
divergent differentiation, lymph node status, margin status, and presence of angiolymphatic invasion or 
urothelial carcinoma in situ. Cytology specimens were reviewed for confirmation of diagnosis, as well as 
upper tract origin (per requisition form).  
2.3 Biopsy, cytology and Resection concordance  
Pre-operative endoscopic biopsy diagnoses and surgical resection diagnoses were assessed for 
concordance with respect to grade, presence of absence of invasion, and presence of absence of 
divergent differentiation, with the RNU or UT resection considered to be the “gold standard.”  
2.4 Patient treatment, follow-up and outcomes  
Patient demographics, receipt of neoadjuvant chemotherapy or adjuvant therapy of any kind, and 
clinical follow-up including recurrence, distant metastasis, and death were also documented.  
 
3. Results 
3.1 Cohort Summary 
The cohort of 114 patients included 85 (85/114, 75%) male and 29 (29/114, 25%) female patients with a 
mean age of 70 years (range 47-94 years). Of the 117 resections from these 114 patients, 101 resections 
(101/117, 86%) from 97 patients had corresponding ipsilateral preoperative biopsy specimens available 
for review. Fifty-four resections (54/117, 46%) from 53 patients had ipsilateral preoperative upper tract 
cytology specimens available for review. Twenty patients had previously undergone cystectomy for 
primary bladder urothelial carcinoma, and one additional patient underwent cystectomy at the same 
time as upper tract resection. Clinical information for the cohort is summarized in Table 1. Eighteen 
(18/117, 15%) resections lacked any in-house pre-operative pathologic material (biopsy or cytology) 
diagnostic of carcinoma. Of these eighteen patients, three had only negative cytology and no biopsy  
(3/18, 17%), 3 had only atypical cytology and no biopsy (3/18, 17%), 1 negative cytology and no 
neoplastic diagnosis on biopsy (1/18, 6%), 1 had atypical cytology and no neoplastic diagnosis on biopsy 
(1/18, 6%), and 10 had no cytology and no neoplastic diagnosis on biopsy (10/18, 56%).    
3.2 Decision for Resection  
Review of clinical notes demonstrated that the results of upper tract biopsy and/or cytology specimens 
influenced the decision to proceed to RNU or UT in 73 cases (73/117, 62%). In the remaining 44 cases, 
the decision to proceed with RNU or UT was made based on clinical features, including size in 23 (23/44, 
52%), multifocal disease in 3 (3/44, 7%), hydronephrosis or other imaging findings (3/44, 7%), presence 
in an area that is difficult to access endoscopically (2/44, 5%), or presence of residual/recurrent tumor 
despite therapy (5/44, 11%). In the remaining 8 (8/44, 18%) cases, there was a combination of more 
than one of the previously listed clinical features that influenced the decision for resection.  
3.3 Histolgic Features of Resections  
The clinicopathologic resection characteristics are summarized in Table 2.  Tumor size information was 
available in 112 resections (out of the 117 resections, 96% cases). In the cases where there were was 
multifocal disease and multiple measurements of foci of carcinoma was taken, the largest size was 
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recorded. Overall, the average recorded tumor size was 3.6 cm (range 0.15 – 22.4 cm). The majority of 
the surgically resected tumors (n=101, 101/117, 86%) showed papillary architecture; however, 6 (6/101, 
6%) of these resections demonstrated both inverted and papillary growth. In 5 resections (5/117, 4%) 
the tumor showed only inverted architecture. Urothelial carcinoma in situ was the only disease on 
resection in 3 cases (3/117, 3%). Invasive carcinoma without a papillary component was present on 
resection in 8 cases (8/117, 7%). Fifty-two (52/117, 44%) cases at the time of resection demonstrated 
noninvasive urothelial carcinoma, out of which 24 (24/52, 46%) were low-grade and the remainder high-
grade. Sixty-five cases (65/117, 56%) demonstrated invasive urothelial carcinoma; 13 (13/65, 20%) 
demonstrated presence of divergent histologic features. Divergent histologic features were reported 
only for invasive tumor, and the divergent features identified included squamous features in 7 (7/13, 
54%) cases, micropapillary in 4 (4/13, 31%) cases, sarcomatoid in 2 (2/13, 15%), glandular in 2 (2/13, 
15%), neuroendocrine in 1 (1/13, 8%), and nested in 1 case (1/13, 8%). Three resections had multiple 
divergent features within the same tumor.  In terms of pathologic stage (utilizing AJCC 7th edition [11]), 
pTa was the most common, occurring in 48 (48/117, 41%) resections; the remainder of the cases 
included 3 (3/117, 3%) pTis, 24 (24/117, 21%) pT1, 12 (12/117, 10%) pT2, 26 (26/117, 22%) pT3, and 3 
(3/117, 3%) pT4 (Table 3).   
3.4 Histologic Features of Preoperative Biopsies 
Among the 101 resections with pre-operative endoscopic biopsies available for review, 14 (14/101,  
14%) biopsies (from 14 patients) were negative for neoplasm. Nine of these biopsies were benign and/or 
reactive, including 6 with fragments of benign urothelium, 1 with benign renal parenchyma only, and 2 
with granulation tissue. Of the remaining non-neoplastic biopsies (5), 1 did not survive processing, 1 
showed only rare epithelial cells, 1 showed acellular debris, 1 showed stroma with crush artifact, and 1 
showed cauterized urothelium with focal keratinizing squamous metaplasia.  Renal pelvis biopsies 
lacking neoplastic diagnoses included 13% (7/54) of ureteroscopic biopsies and 13% (1/8) of 
percutaneous biopsies. Ureter biopsies lacking neoplastic diagnoses included 24% (5/21) from the distal 
ureter, 0% (0/8) from the mid ureter, and 10% (1/10) from the proximal ureter. Photomicrographs of 
representative non-diagnostic biopsies are shown in Figure 1. The remaining 87 resections (87/101, 
86%; from 83 patients) had pre-operative endoscopic upper urinary tract biopsies with neoplastic 
diagnoses. These included 23 noninvasive low-grade papillary urothelial carcinoma (23/87, 26%), 4 
urothelial carcinoma in situ (4/87, 5%), 36 noninvasive high-grade papillary urothelial carcinoma (36/87, 
41%), and 24 invasive high-grade papillary urothelial carcinoma (24/87, 28%). Divergent histology was 
identified in one biopsy. 74% (75/101) of biopsies had subepithelial tissue present for evaluation. The 
biopsy findings are summarized in Table 4.  
67 (67/87, 77%) diagnostic biopsies had subepithelial tissue present for evaluation. These included 77% 
(36/47) ureteroscopic biopsies from renal pelvis, 100% (7/7) percutaneous biopsies from renal pelvis, 
75% (12/16) ureteroscopic biopsies from distal ureter, 63% (5/8) ureteroscopic biopsies from mid 
ureter, and 78% (7/9) biopsies from proximal ureter. Definitive muscularis propria was present in 4% 
(2/47) of ureteroscopic biopsies from renal pelvis, 19% (3/16) from distal ureter, 0% (0/8) from mid 
ureter, and 0% (0/9) from proximal ureter.  
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3.5 Concordance between Preoperative biopsy and subsequent resesction 
The concordance rates of the 87 diagnostic biopsies with subsequent RNU or UT grade, invasion and 
presence of divergent features are shown in Table 5. Overall, 11% (10/87) biopsies demonstrated a 
change in grade which included 3 from noninvasive low-grade papillary urothelial carcinoma to 
noninvasive high-grade papillary urothelial carcinoma (3/10, 30%), 4 changed from noninvasive low-
grade papillary urothelial carcinoma to invasive high-grade urothelial carcinoma (4/10, 40%), and 3 were 
downgraded from noninvasive high-grade papillary urothelial carcinoma to noninvasive low-grade 
papillary urothelial carcinoma (3/10, 30%). All 33 ureter biopsies showed concordant grade on biopsy 
and resection; however, grade was increased at the time of resection for 7 renal pelvis UTUC and 
decreased for 3 renal pelvis UTUC. Overall, 30% (26/87) of cases with diagnostic biopsies were upstaged 
from noninvasive to invasive at the time of resection, including 6 noninvasive low-grade papillary 
urothelial carcinoma to invasive urothelial carcinoma (6/26, 23%; 2 low-grade and 4 high-grade), 18 
noninvasive high-grade papillary urothelial carcinoma to invasive urothelial carcinoma (18/26, 69%), and 
2 urothelial carcinoma in situ to invasive urothelial carcinoma (2/26, 8%). Of the 18 cases reclassified 
from noninvasive high-grade papillary urothelial carcinoma on biopsy to invasive urothelial carcinoma 
on resection, 39% (7/18) patients had previously undergone cystectomy for urothelial carcinoma. The 
frequency of prior cystectomy was significantly greater in this upstaged group as compared to the 
biopsy-resection pairs with concordant invasive (2/24, 8%) and noninvasive (4/37, 11%) carcinoma (chi 
square statistic 8.6, p = 0.014). Significant differences in other pre-operative variables between these 
groups were not identified.  
 
3.6 Discordance between biopsies and resections  
26% (14/54) of renal pelvis UTUC with diagnostic biopsies (12 ureteroscopic, 2 percutaneous) were 
upstaged from noninvasive to invasive at the time of resection. Among the tumors that were invasive on 
resection but noninvasive on ureteroscopic biopsy, 83% (10/12) of biopsies included subepithelial tissue. 
In contrast, 74% (26/35) renal pelvis ureteroscopic biopsies that showed concordant invasion status on 
resection included subepithelial tissue. Underlying renal parenchyma was present in all percutaneous 
renal pelvis biopsies. 36% of ureter UTUC with diagnostic biopsies (12/33) were upstaged from 
noninvasive to invasive at the time of resection; 5 biopsies were from distal ureter, 4 from mid ureter, 
and 3 from proximal ureter. There was no statistically significant difference in the rate of upstaging for 
ureter UTUC as compared to renal pelvis UTUC. Subepithelial tissue was present in 80% (4/5) upstaged 
biopsies from distal ureter versus 73% (8/11) with concordant invasion status, 25% (1/4) upstaged 
biopsies from mid ureter versus 100% (4/4) with concordant invasion status, and 33% (1/3) upstaged 
biopsies from proximal ureter versus 100% (6/6) with concordant invasion status. Photomicrographs of 
representative cases where the grade or presence of invasion was changed from biopsy to resection are 
shown in Figure 2.  
 
Twenty-one cases of UTUC had pre-operative biopsies with neoplastic diagnoses, but no pre-operative 
pathologic material suggestive of high-grade disease (no invasion, no high-grade biopsy, no suspicious or 
positive cytology). Five cases including 1 ureter UTUC and 4 renal pelvis UTUC were invasive on resection 
only. The ureter UTUC that was upstaged at the time of resection had negative cytology but showed  
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radiologic evidence of hydronephrosis. Two renal pelvis UTUC that were upstaged at the time of 
resection had atypical cytology; the other 2 renal pelvis UTUC did not have cytology material available. 
Six renal pelvis UTUC were called high-grade on resection alone; of these, only 1 had cytology, which 
was atypical.   
3.7 Preoperative Upper Tract Cytology  
Fifty-four resections had ipsilateral pre-operative upper urinary tract cytology specimens obtained 
within the year prior to resection and available for review. Cytologic diagnoses were correlated with 
diagnoses from 41 surgical resections of high-grade UTUC from 40 patients, 1 surgical resection of 
urothelial carcinoma in situ from 1 patient, and 12 surgical resections of low-grade UTUC from 12 
patients. The majority of resections with high-grade UTUC (36/41, 88%) had abnormal cytology results 
prior to surgery, including 12 (12/36, 33%) positive, 12 (12/36, 33%) suspicious and 12 (12/36, 33%) 
atypical diagnoses. The resection with UCIS had suspicious pre-operative cytology. While many 
resections with low-grade UTUC had negative pre-operative cytology (5/12, 42%), abnormal results 
included 5 (5/12, 42%) atypical, 1 (1/12, 8%) suspicious, and 1 (1/12, 8%) positive diagnoses. Calculated 
sensitivity and specificity values for detection of high-grade urothelial carcinoma are displayed in Table 
6.  
3.8 Patient Outcomes  
Of the 87 resections with pre-operative neoplastic diagnoses, the biopsy grade was concordant with 
subsequent resection grade in 77 cases. Of these 77 patients, 32 (32/77, 42%) patients had recurrence 
of disease, 20 (20/77, 26%) developed metastasis and 27 (27/77, 35%) of patients died. In the 7 cases 
where the biopsy was low-grade and the resection was high-grade disease (3 noninvasive, 4 invasive), 0 
(0/7, 0%) patients had recurrence of disease, 2 (2/7, 29%) developed metastasis and 2 (2/7, 29%) died. 
In the 3 cases where the biopsy was high-grade and the subsequent resection was low-grade, 1 patient 
(1/3, 33%) had recurrence of disease, 0 (0%) patients developed metastates and 0 (0%) patients died. 
Sixty-one patients had concordant invasion status on biopsy and resection. Of the 24 cases with invasive 
disease on both biopsy and resection (24/61 with concordant invasion status, 39%), 10 developed 
recurrence (10/24, 42%), 14 metastasis (14/24, 58%), and 14 died (14/24, 58%). Of the 37 cases with 
noninvasive disease on both biopsy and resection (37/61, 61%), 13 developed recurrence (13/37, 35%), 
1 metastasis (1/37, 3%), and 6 died (6/37, 16%). Twelve cases with noninvasive carcinoma on biopsy 
were reclassified as T1 after resection of which 6 (6/12, 50%) recurred, 4 (4/12, 33%) developed 
metastasis, and 5 (5/12, 42%) died. Fourteen cases with noninvasive carcinoma on biopsy were 
reclassified as muscle invasive disease (pT2 or higher) after resection; of these, 4 (4/14, 29%) recurred, 3 
(3/14, 21%) developed metastasis, and 4 (4/14, 29%) died. Eight patients had percutaneous biopsies of 
the renal pelvis; of these, 2 (2/8, 25%) developed recurrence (1 in urinary bladder, 1 in urinary bladder 
and contralateral ureter) and 2 (2/8, 25%) metastasized. Outcome information is summarized in Table 7.  
 
4. Discussion:  
Clinical decision-making in patients suspected to have UTUC remains a substantial challenge due to the 
technical limitations of upper urinary tract biopsy and cytology.  Yet, these data indicate that the 
decision to proceed to RNU or UT for treatment of UTUC was often based on biopsy and cytology. 
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Although these provide a relatively accurate assessment of the tumor grade at the time of resection, the 
invasive component of invasive tumors is often not represented on biopsy.   
 
In line with our results, previous studies have shown high concordance of grade reported on 
ureteroscopic biopsy and resection. Rojas et al., reported grade concordance in 92.6% of cases, with 
discordant cases most often being upgraded on resection. [12] In the study by Rojas et al., biopsy 
volume did not affect assessment of tumor grade. Chitale et al., reported 74% overall concordance 
between biopsy and resection in a small cohort (n=19); the only patient with discordant tumor grade 
was upgraded on resection. [13] Of note, however, the discordant tumor was reclassified from World 
Health Organization (WHO) grade 2 to WHO grade 3, so both specimens would be considered to be 
high-grade in nature by current WHO recommendations. Dev et al., also reported grade on a three-point 
scale; however, there was 90% concordance between biopsy and resection grade if grades 2 and 3 are 
reassigned to the high-grade category. [7] Because undergrading of tumor on upper tract biopsy is 
common, intensive follow-up is needed to ensure that high-grade tumor is not present. [14] Other 
groups have also reported from 63 to >90% grade concordance. [15,16,17,18,19]  
 
Upper urinary tract biopsies often provide insufficient material to assess for invasion. In our cohort, 
surgical resections resulted in reclassification of tumor invasion status in nearly one-third (30%) of cases. 
Stage assessment using ureteroscopic biopsy may be difficult. [2] Upper tract biopsy samples are often 
superficial due to the small size of available tools for biopsy. [16,19]. In our study, lamina propria (or 
renal parenchyma) was present in 77% of biopsies with a neoplastic diagnosis. Lamina propria (or renal 
parenchyma) was present in 77% of cases where the biopsy and resection grades were concordant and 
80% of cases where the biopsy and resection invasion was concordant. However, among biopsies from 
mid or proximal ureter, subepithelial tissue was less likely to be present in those cases that were called 
noninvasive on biopsy but invasive on resection. Although it has been proposed that accurate staging 
may be more difficult with larger tumors, the mean tumor size was larger in the concordant (4.4 cm) 
cohort in comparison to the upstaged (3.6 cm) group in our study. Among tumors diagnosed as 
noninvasive high-grade papillary urothelial carcinoma on biopsy and invasive high-grade urothelial 
carcinoma on resection, mean size was 2.8 cm. Rojas et al., reported stage concordance in 43% of cases, 
while the other 57% were upstaged. [12] In their cohort, 59% of biopsies contained subepithelial 
connective tissue. Smith et al., found a similar rate of stage concordance. [17] Chitale et al., reported 
16% of tumors showing invasion at the time of resection did not have invasion detected on biopsy, while 
5% showed downstaging. [13] Guarnizo et al., found that biopsies were approximately 63% accurate in 
staging of UTUC (50% for renal pelvis and 71% for ureter). [16] Presence of high-grade tumor generally 
prompts definitive resection whether or not invasion is present, so this may not represent a significant 
limitation. However, some authors advocate for more conservative therapy of small, solitary 
noninvasive tumors, particularly when the patient’s contralateral kidney is compromised. [20] In such 
instances, accurate assessment of the invasion status of the tumor is necessary. Modern radiologic 
techniques lack the sensitivity to make this distinction as well. [21] Notably, prior radical cystectomy for 
urinary bladder urothelial carcinoma may be a signal to treat more aggressively. 39% (7/18) UTUC 
reclassified from noninvasive high-grade papillary urothelial carcinoma on biopsy to invasive urothelial 
carcinoma on resection were seen in patients who had previously undergone cystectomy. Patients had 
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prior cystectomy in only 8% (2/24) UTUC with invasion on both biopsy and resection and 11% (4/37) 
UTUC without invasion on either biopsy or resection. Of the 8 patients in our cohort who underwent 
percutaneous biopsy of the renal pelvis, none had recurrences along the needle tract.  
 
In our cohort, 14% of upper urinary tract biopsies failed to detect a neoplasm that was subsequently 
resected. As described above, the non-diagnostic biopsies in this cohort were either due to negative 
biopsies (benign or reactive urothelium or normal renal parenchyma) or inadequate sampling. Similarly, 
87% of the 75 upper urinary tract biopsies in the cohort reported by Dev et al., demonstrated UTUC. [7] 
In our study, the biopsies that failed to detect neoplasm were slightly more commonly from the renal 
pelvis (57%). These findings are similar to a previous study which demonstrated that almost one in four 
renal pelvis biopsies had inadequate tissue for a definitive diagnosis. [8] Common issues  preventing 
definitive diagnosis included scant tissue, absence of papillary fronds, crush artifact, and distorted 
architecture. [8] Chen et al., reported that the sensitivity of ureteroscopic biopsy/cytology to detect 
recurrence after UTUC resection is 93.4%. [22]  
 
Previous studies have shown that voided urine cytology is less sensitive for diagnosis of UTUC than it is 
for diagnosis of urinary bladder UC; therefore, direct sampling from the upper urinary tract is preferable. 
[23] A recent meta-analysis of articles comparing upper tract cytology to resection and/or biopsy 
diagnoses demonstrated 55% sensitivity and 91% specificity. [9] Sensitivity of positive upper tract urine 
cytology has been reported to be as high as 81% in some cohorts. [10] The sensitivity of a positive upper 
tract cytology specimen for high-grade UC (HGUC) is 29% in this study, with specificity of 92%. When 
both positive and suspicious diagnoses are included, there is a sensitivity of 58% and specificity of 83% 
for HGUC. With inclusion of any abnormal cytology diagnosis, the sensitivity increases to 88% , although 
specificity drops to 42%. Skolarikos et al., reported that tumors that were noninvasive on biopsy but had 
positive cytology were more likely to show invasion at the time of resection. [19] Williams et al., 
similarly reported an increased positive predictive value of muscle invasive disease in those patients 
with positive cytology, although this result did not achieve statistical signifiance. [18] In our cohort, 
there was not a significant difference in the rates of positive and suspicious cytology between the 
groups that were upstaged on resection compared to biopsy (4/10, 40%) and concordant (11/24, 46%) 
groups.  
 
Strengths of this study include the use of a large cohort of patients from a single tertiary care academic 
center, who underwent RNU or UT for UTUC, with available clinical follow-up. Limitations of the study 
include the fact that only in-house biopsy and cytology specimens were available for re-review, and 
therefore outside specimens were not available for pathologic assessment. On a related note, the 
patient population at our tertiary care center may not necessarily be representative of the general 
population. Additionally, our cohort was selected based on the presence of cancer at the time of the 
resection (acting as the gold standard for diagnosis); patients who received more conservative 
treatment were therefore not included.  
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In conclusion, although upper urinary tract biopsy has significant technical limitations, a substantial 
proportion of specimens demonstrate presence of malignant neoplasm and grade concordance is high 
between biopsy and resection specimens. Upper urinary tract biopsies are often inadequate for 
assessment of invasion status. Despite the significant subset of cases with reclassification of grade 
and/or invasive status at the time of resection, most adverse patient outcomes were seen in cases with 
concordant grade and invasive status on the biopsy and resection.  
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FIGURE LEGENDS:  
 
Figure 1. Histologic Examples of Non-Diagnostic Biopsies (Hematoxylin and Eosin, 100x). Non-
diagnostic biopsies occurred in both the renal pelvis (A-D) and the ureter (E-F). Examples of biopsies that 
were considered non-diagnostic include those with: extensive crush artifact (A), scant amounts of 
acellular debris (B), clotted blood/fibrin with rare detached single cells (C), subepithelial connective 
tissue and granulation tissue only with no epithelial component present (D), ulcerated granulation tissue 
(E) and scant urothelium with reactive changes (F).   
 
 
Figure 2. Examples of Discordant Biopsies and Resections (Hematoxylin and Eosin, 200x). A-B. An 
example of a case in which the biopsy (A) was called noninvasive low-grade UCa and the resection (B) 
was  called noninvasive high-grade UCa. C-D. An example in which the biopsy (C) was called noninvasive 
high-grade UCa and the subsequent resection (D) was called noninvasive low-grade UCa. E-F. An 
example case in which the biopsy (E) was noninvasive high-grade UCa and the resection (F) was invasive 
high-grade UCa.  
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Table 1. Clinical Cohort of 114 patients. 
Gender, n (%) Male 85 (75) 
Female 29 (25) 
Age at time of resection, years Range 47-94 
Mean 70 
Median 58 
Previous cystectomy for bladder 
cancer, n (%) 
 20 (18) 
Neoadjuvant chemotherapy, n 
(%) 
 12 (10) 
Pre-resection upper tract 
biopsy, n (%) 
 97 (85) 
Pre-resection upper tract 
cytology specimen, n (%) 
 53 (46) 
High-grade biopsy or cytology 
specimen 
 78 (68) 
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Table 2. Pathologic Features of Upper Tract Resection Specimens. 
Laterality, n (%) Right 44 (38) 
Left 73 (62) 
Location, n (%) Renal pelvis 64 (55) 
Ureter 34 (29) 
Renal pelvis and ureter 19 (16) 
Focality, n (%) Unifocal 80 (68) 
Multifocal 37 (32) 
Size, cm  Range 0.15- 22.4 
Mean 3.6 
Median 2.7 
Grade, n (%) Low 26 (22) 
High 91 (78) 
Architecture, n (%) Papillary 95 (81) 
Inverted 5 (4) 
Flat 3 (3) 
Invasive 8 (7) 
Multiple Patterns 6 (5) 
Divergent Features Present, n 
(%) 
  13 (20) 
Carcinoma in Situ Present, n (%)   44 (38) 
Angiolymphatic Invasion 
Present, n (%) 
  16 (14) 
Final Surgical Margins, n (%) Negative 111 (95) 
Positive for Dysplasia 1 (1) 
Positive for Carcinoma 5 (4) 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
16 
 
Table 3. Pathologic Stage of Upper Tract Resection Specimens. 
T Stage, n (%) Tis 3 (3) 
Ta 49 (42) 
T1 24 (21) 
T2 12 (10) 
T3 26 (22) 
T4 3 (3) 
N Stage, n (%) NX 64 (55) 
N0 46 (39) 
N1 2 (2) 
N2 5 (4) 
M Stage, n (%) MX 110 (94) 
M1 7 (6) 
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Table 4. Pathologic Features of Upper Tract Biopsy Specimens with Neoplasm 
Laterality, n (%) Right 31 (36) 
Left 56 (64) 
Location, n (%) Renal pelvis 53 (61) 
Ureter 34 (39) 
Grade, n (%) Low 23 (26) 
High 64 (74) 
Invasion Present, n (%)  24 (28) 
Divergent Features Present, n 
(%) 
  1 (1) 
Subepithelial Tissue Present, n 
(%) 
  67 (77) 
Muscularis Propria Present, n 
(%) 
  5 (6) 
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Table 5. Concordance of Diagnostic Biopsies with Subsequent Resection.  
  Discordant ↓ Concordant Discordant ↑ 
Grade, n (% diagnostic biopsies) 3 (3) 77 (89) 7 (8) 
Invasion, n (% diagnostic 
biopsies) 
0 (0) 61 (70) 26 (30) 
Divergent Features, n (% 
diagnostic biopsies for invasive 
UCa) 
0 (0)  1 (8) 12 (92) 
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Table 6. Sensitivity and specificity of pre-operative upper tract cytology specimens for high-grade 
urothelial carcinoma.  
Cytology Result Number of cases n=53 
Sensitivity for High 
Grade UCA 
Specificity for High 
Grade UCA 
Positive, n (%) 13 (25) 0.29 0.92 
Positive or Suspicious, 
n (%) 27 (54) 0.58 
 
0.83 
Positive, Suspicious, or 
Atypical, n (%) 44 (83) 0.88 
 
 
0.42 
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Table 7. Patient Outcomes Based on Concordance of Diagnostic Biopsy and Resection Grade.  
  Grade Invasion 
 Concordant 
n=77 
Discordant, 
↑ time of 
Resection 
n= 7 
Discordant, 
↓ at time of 
Resection 
n= 3 
Concordant 
n= 61 
Discordant, 
↑ time of 
Resection 
n=26 
 
Discordant, 
↓ at time of 
Resection 
n= 0 
Recurrence, 
n (% 
diagnostic  
biopsies) 
32 (42) 0 (0) 1 (33) 23 (38) 10 (38) 0 (0) 
Metastasis, 
n (% 
diagnostic 
biopsies) 
20 (26) 2 (29) 0 (0) 15 (25) 7 (27) 0 (0) 
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Highlights: 
 For upper tract urothelial carcinomas (UTUC), grade concordance between biopsy and resection 
is high 
 In nearly one-third of cases, invasion is diagnosed on resection but not apparent on biopsy 
 Subepithelial tissue is less commonly present in biopsies from the mid or proximal ureter 
 UTUC in patients with prior cystectomy were more likely to show invasion on resection but not 
biopsy 
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